X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs MERCK LTD - Comparison Results

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA MERCK LTD SHASUN PHARMA/
MERCK LTD
 
P/E (TTM) x 123.9 33.2 373.6% View Chart
P/BV x 8.5 3.7 229.8% View Chart
Dividend Yield % 0.2 0.8 30.6%  

Financials

 SHASUN PHARMA   MERCK LTD
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
MERCK LTD
Dec-16
SHASUN PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs941,060 8.9%   
Low Rs46623 7.3%   
Sales per share (Unadj.) Rs214.2632.4 33.9%  
Earnings per share (Unadj.) Rs5.345.7 11.7%  
Cash flow per share (Unadj.) Rs15.862.3 25.4%  
Dividends per share (Unadj.) Rs1.0011.00 9.1%  
Dividend yield (eoy) %1.41.3 109.4%  
Book value per share (Unadj.) Rs53.3388.8 13.7%  
Shares outstanding (eoy) m56.6216.60 341.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.3 24.5%   
Avg P/E ratio x13.118.4 71.2%  
P/CF ratio (eoy) x4.413.5 32.7%  
Price / Book Value ratio x1.32.2 60.6%  
Dividend payout %18.724.1 77.9%   
Avg Mkt Cap Rs m3,95813,969 28.3%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m2,1641,487 145.5%   
Avg. sales/employee Rs ThNM6,631.9-  
Avg. wages/employee Rs ThNM939.2-  
Avg. net profit/employee Rs ThNM479.4-  
INCOME DATA
Net Sales Rs m12,12710,498 115.5%  
Other income Rs m229242 94.6%   
Total revenues Rs m12,35610,741 115.0%   
Gross profit Rs m1,0091,135 88.9%  
Depreciation Rs m594276 215.5%   
Interest Rs m4150-   
Profit before tax Rs m2301,102 20.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73343 -21.2%   
Profit after tax Rs m302759 39.8%  
Gross profit margin %8.310.8 76.9%  
Effective tax rate %-31.731.1 -101.6%   
Net profit margin %2.57.2 34.5%  
BALANCE SHEET DATA
Current assets Rs m6,8846,410 107.4%   
Current liabilities Rs m8,4568,828 95.8%   
Net working cap to sales %-13.0-23.0 56.2%  
Current ratio x0.80.7 112.1%  
Inventory Days Days6258 106.8%  
Debtors Days Days10838 280.2%  
Net fixed assets Rs m4,9701,406 353.4%   
Share capital Rs m113166 68.3%   
"Free" reserves Rs m2,8756,286 45.7%   
Net worth Rs m3,0206,455 46.8%   
Long term debt Rs m1,8170-   
Total assets Rs m13,3478,828 151.2%  
Interest coverage x1.6NM-  
Debt to equity ratio x0.60-  
Sales to assets ratio x0.91.2 76.4%   
Return on assets %5.48.6 62.5%  
Return on equity %10.011.8 85.1%  
Return on capital %13.317.1 78.0%  
Exports to sales %46.48.3 559.8%   
Imports to sales %14.221.0 67.7%   
Exports (fob) Rs m5,622869 646.6%   
Imports (cif) Rs m1,7282,209 78.2%   
Fx inflow Rs m5,843959 609.4%   
Fx outflow Rs m2,1732,612 83.2%   
Net fx Rs m3,669-1,653 -222.0%   
CASH FLOW
From Operations Rs m3981,070 37.1%  
From Investments Rs m-1,635-750 218.1%  
From Financial Activity Rs m1,309-150 -873.6%  
Net Cashflow Rs m71171 41.7%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 3.6 18.2 19.8%  
FIIs % 17.6 1.0 1,760.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 29.1 136.1%  
Shareholders   20,750 28,591 72.6%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   VENUS REMEDIES  DR. REDDYS LAB  NOVARTIS  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS